Next 10 |
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a collaboration to conduct an investigator-spo...
2024-05-10 06:33:54 ET More on eFFECTOR Therapeutics eFFECTOR stock slides on decision to discontinue development of tomivosertib for lung cancer treatment Seeking Alpha’s Quant Rating on eFFECTOR Therapeutics Historical earnings data for eFFECTOR Therapeutics...
Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025 SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 09, 202...
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will presen...
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
2024-04-04 13:06:43 ET More on Mid-day movers & stocks. Seeking Alpha’s Quant Rating on Barinthus Biotherapeutics Historical earnings data for Barinthus Biotherapeutics Financial information for Barinthus Biotherapeutics Seeking Alpha’s Quan...
A look at the top 10 most actives in the United States WiSA Technologies Inc. (WISA) rose 0.8% to $0.0245 on volume of 49,663,616 shares TC BioPharm (Holdings) plc (TCBP) rose 134.2% to $3.045 on volume of 39,956,892 shares Nikola Corporation (NKLA) rose 8.1% to $0.963899 on volume of 31,...
2024-04-04 09:34:00 ET eFFECTOR Therapeutics ( NASDAQ: EFTR ) shares fell about 77% after it said that it will stop developing tomivosertib to treat frontline non-small cell lung cancer after disappointing results from mid-stage trial. “While there was evidence of ...
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced topline results from the primary analysis of...
2024-03-27 20:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
eFFECTOR Therapeutics Inc. Company Name:
EFTR Stock Symbol:
NASDAQ Market:
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a collaboration to conduct an investigator-spo...
Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025 SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 09, 202...
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will presen...